Free Trial

Nektar Therapeutics (NKTR) SEC Filings & 10K Form

Nektar Therapeutics logo
$0.82 +0.00 (+0.10%)
Closing price 03/12/2025 04:00 PM Eastern
Extended Trading
$0.88 +0.06 (+7.32%)
As of 03/12/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Nektar Therapeutics SEC Filings

DateFilerForm TypeView
02/24/2025
6:10 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/21/2025
5:04 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2025
5:06 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2025
5:07 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
2:27 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2025
2:18 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/19/2025
2:21 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
12:49 PM
Nektar Therapeutics (Subject)
SAMLYN CAPITAL, LLC (Filed by)
Form SCHEDULE 13G
02/14/2025
11:08 AM
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Nektar Therapeutics (Subject)
Form SCHEDULE 13G/A
02/14/2025
7:43 AM
Deep Track Capital, LP (Filed by)
Nektar Therapeutics (Subject)
Form SCHEDULE 13G/A
01/17/2025
7:37 PM
GREER R SCOTT (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:39 PM
Nektar Therapeutics (Issuer)
WHITFIELD ROY A (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:30 PM
Ajer Jeffrey Robert (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:32 PM
Brainard Diana (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
01/17/2025
7:35 PM
CHESS ROBERT (Reporting)
Nektar Therapeutics (Issuer)
Form 5
Annual statement of changes in beneficial ownership of securities  
12/26/2024
6:04 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/26/2024
8:35 AM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2024
2:21 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/20/2024
7:33 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2024
8:08 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2024
2:12 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/18/2024
3:17 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2024
7:54 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
7:54 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
7:55 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
2:29 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
8:24 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/20/2024
7:37 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2024
7:36 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2024
7:36 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2024
2:17 PM
Nektar Therapeutics (Subject)
ROBIN HOWARD W (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2024
2:28 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
11:17 AM
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G
11/14/2024
8:18 AM
Deep Track Capital, LP (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G/A
11/08/2024
4:31 PM
BlackRock, Inc. (Filed by)
Nektar Therapeutics (Subject)
Form SC 13G
11/07/2024
3:31 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
7:52 AM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2024
8:15 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
8:15 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
8:14 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2024
3:13 PM
Nektar Therapeutics (Subject)
Wilson Mark Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
$2 Trillion Disappears Because of Fed's Secretive New Move (Ad)

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.
08/19/2024
2:45 PM
Nektar Therapeutics (Subject)
Zalevsky Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/14/2024
5:02 PM
CHESS ROBERT (Reporting)
Nektar Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
11:15 PM
Nektar Therapeutics (Filer)
Form EFFECT
06/05/2024
4:30 PM
Nektar Therapeutics (Filer)
Form 424B3
05/28/2024
3:51 PM
Nektar Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
05/20/2024
8:12 PM
Nektar Therapeutics (Issuer)
Wilson Mark Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
8:13 PM
Nektar Therapeutics (Issuer)
Zalevsky Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2024
8:14 PM
Nektar Therapeutics (Issuer)
ROBIN HOWARD W (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2024
3:36 PM
Deep Track Biotechnology Master Fund, Ltd. (Reporting)
Deep Track Capital, LP (Reporting)
KROIN DAVID (Reporting)
Nektar Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
3:20 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/26/2024
3:12 PM
Nektar Therapeutics (Filer)
Form ARS
04/17/2024
4:03 PM
Nektar Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/19/2024
3:38 PM
Nektar Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
03/15/2024
3:18 PM
Nektar Therapeutics (Subject)
TCG Crossover GP II, LLC (Filed by)
Form SC 13G
03/14/2024
3:30 PM
Deep Track Biotechnology Master Fund, Ltd. (Reporting)
Deep Track Capital, LP (Reporting)
KROIN DAVID (Reporting)
Nektar Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners